Email this page: News Release

OncoGenex Pharmaceuticals Completes Amendment to Phase 3 Special Protocol Assessment for Confirming Survival Benefit in Patients Receiving OGX-011 with First-Line Docetaxel for Metastatic Prostate Cancer

To (email address):   Separate multiple addresses with commas. Maximum 200 characters.
Your name:
Your email address:   Copy yourself These email addresses will be used to email the page on your behalf and will not be used by OncoGenex Pharmaceuticals, Inc. for any marketing purposes.
Add a comment:
Send:    Full page    Link to page
Type in number:
This helps OncoGenex Pharmaceuticals, Inc. prevent automated submissions.